Cargando…
Intensity of metastasis screening and survival outcomes in patients with breast cancer
Previous randomized trials, performed decades ago, showed no survival benefit of intensive screening for distant metastasis in breast cancer. However, recent improvements in targeted therapies and diagnostic accuracy of imaging have again raised the question of the clinical benefit of screening for...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854644/ https://www.ncbi.nlm.nih.gov/pubmed/33531549 http://dx.doi.org/10.1038/s41598-021-82485-w |
_version_ | 1783646124148523008 |
---|---|
author | Cheun, Jong-Ho Jung, Jigwang Lee, Eun-Shin Rhu, Jiyoung Lee, Han-Byoel Lee, Kyung-Hun Kim, Tae-Yong Han, Wonshink Im, Seock-Ah Noh, Dong-Young Moon, Hyeong-Gon |
author_facet | Cheun, Jong-Ho Jung, Jigwang Lee, Eun-Shin Rhu, Jiyoung Lee, Han-Byoel Lee, Kyung-Hun Kim, Tae-Yong Han, Wonshink Im, Seock-Ah Noh, Dong-Young Moon, Hyeong-Gon |
author_sort | Cheun, Jong-Ho |
collection | PubMed |
description | Previous randomized trials, performed decades ago, showed no survival benefit of intensive screening for distant metastasis in breast cancer. However, recent improvements in targeted therapies and diagnostic accuracy of imaging have again raised the question of the clinical benefit of screening for distant metastasis. Therefore, we investigated the association between the use of modern imaging and survival of patients with breast cancer who eventually developed distant metastasis. We retrospectively reviewed data of 398 patients who developed distant metastasis after their initial curative treatment between January 2000 and December 2015. Patients in the less-intensive surveillance group (LSG) had significantly longer relapse-free survival than did patients in the intensive surveillance group (ISG) (8.7 vs. 22.8 months; p = 0.002). While the ISG showed worse overall survival than the LSG did (50.2 vs. 59.9 months; p = 0.015), the difference was insignificant after adjusting for other prognostic factors. Among the 225 asymptomatic patients whose metastases were detected on imaging, the intensity of screening did not affect overall survival. A small subgroup of patients showed poor survival outcomes when they underwent intensive screening. Patients with HR-/HER2 + tumors and patients who developed lung metastasis in the LSG had better overall survival than those in the ISG did. Highly intensive screening for distant metastasis in disease-free patients with breast cancer was not associated with significant survival benefits, despite the recent improvements in therapeutic options and diagnostic techniques. |
format | Online Article Text |
id | pubmed-7854644 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78546442021-02-03 Intensity of metastasis screening and survival outcomes in patients with breast cancer Cheun, Jong-Ho Jung, Jigwang Lee, Eun-Shin Rhu, Jiyoung Lee, Han-Byoel Lee, Kyung-Hun Kim, Tae-Yong Han, Wonshink Im, Seock-Ah Noh, Dong-Young Moon, Hyeong-Gon Sci Rep Article Previous randomized trials, performed decades ago, showed no survival benefit of intensive screening for distant metastasis in breast cancer. However, recent improvements in targeted therapies and diagnostic accuracy of imaging have again raised the question of the clinical benefit of screening for distant metastasis. Therefore, we investigated the association between the use of modern imaging and survival of patients with breast cancer who eventually developed distant metastasis. We retrospectively reviewed data of 398 patients who developed distant metastasis after their initial curative treatment between January 2000 and December 2015. Patients in the less-intensive surveillance group (LSG) had significantly longer relapse-free survival than did patients in the intensive surveillance group (ISG) (8.7 vs. 22.8 months; p = 0.002). While the ISG showed worse overall survival than the LSG did (50.2 vs. 59.9 months; p = 0.015), the difference was insignificant after adjusting for other prognostic factors. Among the 225 asymptomatic patients whose metastases were detected on imaging, the intensity of screening did not affect overall survival. A small subgroup of patients showed poor survival outcomes when they underwent intensive screening. Patients with HR-/HER2 + tumors and patients who developed lung metastasis in the LSG had better overall survival than those in the ISG did. Highly intensive screening for distant metastasis in disease-free patients with breast cancer was not associated with significant survival benefits, despite the recent improvements in therapeutic options and diagnostic techniques. Nature Publishing Group UK 2021-02-02 /pmc/articles/PMC7854644/ /pubmed/33531549 http://dx.doi.org/10.1038/s41598-021-82485-w Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Cheun, Jong-Ho Jung, Jigwang Lee, Eun-Shin Rhu, Jiyoung Lee, Han-Byoel Lee, Kyung-Hun Kim, Tae-Yong Han, Wonshink Im, Seock-Ah Noh, Dong-Young Moon, Hyeong-Gon Intensity of metastasis screening and survival outcomes in patients with breast cancer |
title | Intensity of metastasis screening and survival outcomes in patients with breast cancer |
title_full | Intensity of metastasis screening and survival outcomes in patients with breast cancer |
title_fullStr | Intensity of metastasis screening and survival outcomes in patients with breast cancer |
title_full_unstemmed | Intensity of metastasis screening and survival outcomes in patients with breast cancer |
title_short | Intensity of metastasis screening and survival outcomes in patients with breast cancer |
title_sort | intensity of metastasis screening and survival outcomes in patients with breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854644/ https://www.ncbi.nlm.nih.gov/pubmed/33531549 http://dx.doi.org/10.1038/s41598-021-82485-w |
work_keys_str_mv | AT cheunjongho intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT jungjigwang intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT leeeunshin intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT rhujiyoung intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT leehanbyoel intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT leekyunghun intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT kimtaeyong intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT hanwonshink intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT imseockah intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT nohdongyoung intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT moonhyeonggon intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer |